Citing the spread of infections linked to rising rates of opioid use across the country including HIV, viral hepatitis, skin and soft tissue infections, bone and joint infections and endocarditis

The Kentucky governor’s decision this week to voice support for the irresponsible practice of deliberately exposing children to chickenpox as an alternative to vaccination is gravely concerning.

The White House budget proposal for 2020 recommends increases to the domestic HIV programs at the U.S. Centers for Disease Control and Prevention, the Health Resources and Services Administration and Indian Health Services that will be essential to keeping the administration’s promise of ending our nation’s HIV epidemic in the next decade.

The NHAS has served as a critical roadmap for strengthening our nation’s response to the HIV epidemic, and a strong commitment to ensuring the NHAS’ continued relevance as an evidence-based and outcomes-oriented guide is important to not lose ground and to achieve the administration’s proposal to end the HIV epidemic.

Despite the emphatic objections from medical providers’ associations nationwide, including the HIV Medicine Association, the administration has chosen to compromise the crucial trust between physicians and patients, further erode access to basic healthcare

A District Court injunction preventing the military discharge of two Air Force members living with HIV was responsive to medical evidence and reflected important recognition of advances in treatment for HIV

The President’s goal to end the HIV epidemic in the United States within the next 10 years, announced in his State of the Union Address is laudable and critically important to the strength and well-being of our nation.

HIVMA recognizes and supports efforts to negotiate lower drug prices and reduce out-of-pocket costs for Medicare beneficiaries.  However, we are concerned that the proposed rule would undermine patient care by eroding Part D policies that were put in place by CMS to negate insurer discriminatory practices. Lower drug prices must not come at the expense of poorer health outcomes for Medicare beneficiaries as one of the goals of reducing is to expand and improve access to high quality health care and treatment.